Where can I buy lecanemab-LEQEMBI in the country?

Lecanemab-LEQEMBI has been approved for marketing in China, but it has not yet been included in medical insurance, so patients mainly rely on self-pay channels when purchasing. Due to the short time to market, drug supply is relatively limited and is currently mainly concentrated in specific pharmacies in some tertiary hospitals and neurology specialty hospitals. If patients need to purchase, they need to consult the hospital or specialist in advance for specific inventory and purchase procedures to ensure smooth access to medicines.

In the domestic market, the supply of lencanezumab is limited and difficult to purchase. Some hospitals will require patients to provide detailed medical records and medication indications, and issue prescriptions after specialist evaluation. This means that patients cannot just go to pharmacies to buy drugs like conventional drugs, but must obtain them through formal medical institutions and the guidance of professional doctors to ensure the safety and rationality of drug use.

Since it is not covered by medical insurance, patients have a greater financial burden to purchase medicines at their own expense. Taking the current market situation as an example, the domestic price reference is close to the overseas US version price, and the cost of each box is about more than 10,000 yuan. For patients with Alzheimer's disease who require long-term medication, the cost is relatively high. Therefore, before taking medication, one should fully assess their financial affordability and develop a reasonable medication plan based on doctor's advice.
In overseas markets, the supply of lencanezumab is relatively sufficient. For example, the US version costs more than 10,000 yuan per box. Patients can obtain it through formal cross-border channels if they have the conditions, but they also need to follow prescription and transportation regulations. When used in China, it is recommended that patients strictly follow the doctor's prescription and regularly follow up and monitor cognitive function and imaging indicators to ensure maximum efficacy and reduce the risk of potential adverse reactions.
Reference: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval